Instem, a provider of early drug development software solutions, has announced that the University of Texas M D Anderson Cancer Center has purchased Provantis 8 for its research facilities in central Texas.
Subscribe to our email newsletter
To begin leveraging a key part of the system right away, M D Anderson deployed Provantis Pathology using Instem’s remote hosted online model, allowing pathologists to access the software over the Internet from any location.
From the time they plan a preclinical study and allocate the resources, right through to final report production, M D Anderson has automated their processes using the following integrated Provantis modules – toxicology resource planning, general toxicology, pathology, clinical pathology, protocol & report assembly, tables & statistics, labeling, and dispense.
Instem additionally provided project management, implementation, validation and training services to M D Anderson during the project.
Provantis is a fully integrated software system for single users and global organizations engaged in non-clinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, Provantis streamlines processes and workflows with straightforward, intuitive functionality for simple and complex studies within a good laboratory practice (GLP) or non-GLP environment, Instem said.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.